Effect of Liraglutide on Pulsatile Insulin Secretion in Subjects With Type 2 Diabetes
NCT ID: NCT01507311
Last Updated: 2017-01-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
11 participants
INTERVENTIONAL
1999-09-30
1999-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Liraglutide on Weight and Appetite in Obese Subjects With Type 2 Diabetes
NCT01508949
Safety and Tolerability of Liraglutide in Healthy Volunteers and Subjects With Type 2 Diabetes
NCT01507285
Effect of Liraglutide on the Beta-cell Responsiveness in Subjects With Type 2 Diabetes Compared to a Healthy Control Group
NCT01511185
Safety and Tolerability of Liraglutide in Healthy Male Volunteers
NCT01507272
Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results
NCT01179048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
NNC 90-1170
liraglutide
A single dose injected subcutaneously (under the skin)
Placebo
placebo
A single dose injected subcutaneously (under the skin)
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
liraglutide
A single dose injected subcutaneously (under the skin)
placebo
A single dose injected subcutaneously (under the skin)
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* BMI (Body Mass Index) between 24 and 35 kg/m\^2 (both inclusive)
* Fasting plasma glucose between 6 and 15 mmol/l (both inclusive)
* Anti-GAD (glutamic acid decarboxylase) negative
Exclusion Criteria
* Receipt of any investigational drug within three months prior to this trial
* Recurrent severe hypoglycaemia as judged by the investigator
* Cardiac disease or any clinically significant abnormal ECG (electrocardiogram)
* Use of any drug (except oral hypoglycaemic agents (OHAs)) which in the investigator's opinion could interfere
* with the blood glucose level (i.e., insulin, systemic corticosteroids, thiazides)
* Liver or renal disease
30 Years
75 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Novo Nordisk A/S
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Global Clinical Registry (GCR, 1452)
Role: STUDY_DIRECTOR
Novo Nordisk A/S
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Novo Nordisk Investigational Site
Århus C, , Denmark
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Juhl CB, Hollingdal M, Sturis J, Jakobsen G, Agerso H, Veldhuis J, Porksen N, Schmitz O. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes. 2002 Feb;51(2):424-9. doi: 10.2337/diabetes.51.2.424.
Related Links
Access external resources that provide additional context or updates about the study.
Clinical Trials at Novo Nordisk
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NN2211-1219
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.